Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 27 January 2016
Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 6 January 2021
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC